Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Mol Ther. 2010 Nov;18(11):1917-26. doi: 10.1038/mt.2010.167. Epub 2010 Aug 10.
Peptide for ocular delivery (POD) is a novel cationic cell-penetrating peptide (CPP) which, when conjugated with polyethylene glycol (PEG-POD), can deliver plasmid DNA to the retinal pigment epithelium (RPE) of adult murine retina. PEG-POD nanoparticles containing an expression cassette for glial cell line-derived neurotrophic factor (PEG-PODGDNF) were investigated for their ability to inhibit light-induced photoreceptor apoptosis. PEG-PODGDNF, control nanoparticles, or buffer were injected into the subretinal space of adult murine retina and retinal degeneration induced by blue light. Animals injected with PEG-PODGDNF showed a significant reduction (3.9-7.7 fold) in apoptosis relative to control-injected animals. The thickness of the outer nuclear layer (ONL) of the superior retina of PEG-PODGDNF-injected eyes was significantly greater (23.6-39.3%) than control-injected retina 14 days post-light treatment. PEG-POD~GDNF-injected eyes showed a 27-39% greater functional response relative to controls, as measured by electroretinogram (ERG) 7 days post-light treatment. This is one of only two studies demonstrating histological and functional rescue of a mouse model of retinal degeneration following nonviral administration of a transgene into adult retina. Although rescue is short lived for clinical application, this study represents an important step in the development of nonviral gene therapy for retinal diseases.
眼部递药肽(POD)是一种新型阳离子细胞穿透肽(CPP),与聚乙二醇(PEG-POD)缀合后,可将质粒 DNA 递送至成年鼠视网膜色素上皮(RPE)。研究了含有胶质细胞系源性神经营养因子(PEG-PODGDNF)表达盒的 PEG-POD 纳米颗粒抑制光诱导的光感受器细胞凋亡的能力。PEG-PODGDNF、对照纳米颗粒或缓冲液被注射到成年鼠的视网膜下腔,并诱导蓝光诱导的视网膜变性。与对照注射动物相比,注射 PEG-PODGDNF 的动物的凋亡明显减少(3.9-7.7 倍)。PEG-PODGDNF 注射眼的上视网膜外核层(ONL)的厚度比对照注射视网膜的厚度增加了 23.6-39.3%(14 天)。与对照相比,在光处理后 7 天通过视网膜电图(ERG)测量,PEG-POD~GDNF 注射眼的功能反应增加了 27-39%。这是仅有的两项研究之一,证明了在成年视网膜中非病毒转染基因治疗后,可挽救小鼠视网膜变性模型的组织学和功能。尽管对于临床应用来说,这种挽救是短暂的,但这一研究代表了开发用于治疗视网膜疾病的非病毒基因治疗的重要一步。